Cabaletta Bio Files 8-K

Ticker: CABA · Form: 8-K · Filed: Nov 18, 2024 · CIK: 1759138

Sentiment: neutral

Topics: 8-K, SEC Filing

TL;DR

Cabaletta Bio filed an 8-K, likely routine updates. Check for specifics.

AI Summary

Cabaletta Bio, Inc. filed an 8-K on November 18, 2024, to report on other events and financial statements. The filing does not contain specific details about new material events, significant financial changes, or executive appointments within the provided text.

Why It Matters

This 8-K filing indicates Cabaletta Bio is providing updates or disclosures required by the SEC, which could contain important information for investors.

Risk Assessment

Risk Level: low — The provided text is a standard 8-K filing header and does not contain specific material events that would inherently increase risk.

Key Players & Entities

FAQ

What specific events are being reported in this 8-K filing by Cabaletta Bio, Inc.?

The provided text indicates the filing is for 'Regulation FD Disclosure', 'Other Events', and 'Financial Statements and Exhibits', but does not detail the specific events within this excerpt.

When was this 8-K filing submitted by Cabaletta Bio, Inc.?

The filing was submitted on November 18, 2024.

What is the principal executive office address for Cabaletta Bio, Inc.?

The principal executive offices are located at 2929 Arch Street, Suite 600, Philadelphia, PA 19104.

What is the exact name of the registrant as specified in its charter?

The exact name of the registrant is Cabaletta Bio, Inc.

What is the SIC code for Cabaletta Bio, Inc.?

The Standard Industrial Classification (SIC) code for Cabaletta Bio, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).

Filing Stats: 2,339 words · 9 min read · ~8 pages · Grade level 15.3 · Accepted 2024-11-18 07:05:36

Key Financial Figures

Filing Documents

Forward-Looking Statements

Forward-Looking Statements The information under this Item 8.01 contains "forward-looking statements" of Cabaletta Bio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including without limitation, express or implied statements regarding: Cabaletta's business plans and objectives as a whole; Cabaletta's ability to realize its vision of launching the first curative targeted cell therapy designed specifically for patients with autoimmune diseases; Cabaletta's ability to successfully complete research and further development and commercialization of its drug candidates in current or future indications, including the timing and results of Cabaletta's clinical trials and its ability to conduct and complete clinical trials; expectation that clinical results will support CABA-201's safety and activity profile; statements regarding the expectations of trial modifications and prophylactic measures, continued trial operations; statements regarding the timing of interactions with regulatory authorities, including such authorities' review of safety information from Cabaletta's ongoing clinical trials and potential registrational program designs for CABA-201; Cabaletta's expectations around the potential success and therapeutic benefits of CABA-201, including its belief that CABA-201 has the potential to reset the immune system and result in compelling clinical responses without chronic therapy requirements in patients; the Company's advancement of separate Phase 1/2 clinical trials of CABA-201 in patients with SLE, myositis, SSc and gMG and advancement of a RESET-PV trial, including updates related to status, safety data, efficiency of clinical trial design or otherwise; the clinical significance of the clinical data read-out at the ACR Convergence 2024 in November 2024 for patients with myositis, SLE and SSc treated with CABA-201; Cabaletta's ability to increase enrollment from its rapidly expanding clinical network in the RESET clinica

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits 99.1 Investor Presentation, dated November 18, 2024, furnished herewith. 99.2 Press Release issued by the registrant on November 18, 2024, furnished herewith. 99.3 Poster presentation from Cabaletta Bio, Inc., dated November 16, 2024 99.4 Slides from Cabaletta Bio, Inc.'s ACR Convergence 2024 Conference Presentation, dated November 17, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CABALETTA BIO, INC. Date: November 18, 2024 By: /s/ Steven Nichtberger Steven Nichtberger, M.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing